复星医药跌5.3% 国联民生2天前维持增持评级

Group 1 - The core viewpoint of the article indicates that Fosun Pharma's stock closed at 29.33 yuan, experiencing a decline of 5.30% [1] - Guolian Minsheng Securities analysts maintain a "buy" rating for Fosun Pharma, highlighting the company's stable operations and year-on-year growth in innovative drugs [1]